F Goncalves

Publications (12)12.58 Total impact

• Article: Value of antibiotic therapy for bioptically proved chronic prostatitis.

  P Kertes, F Goncalves, J Stefancik, J Dubravicky, M Hladik, J Breza
  Bratislavske lekarske listy 02/2008; 109(1):42. · 0.40 Impact Factor
• Article: Pharmacological prevention of prostate cancer.

  F Goncalves, J Brutenic, M Blasko
  Bratislavske lekarske listy 02/2005; 106(11):379. · 0.40 Impact Factor
• Article: Current problems of prostate cancer.

  F Goncalves, M Hornak, D Ondrus, M Miklosi, V Kotula
  [show abstract] [hide abstract]
  ABSTRACT: Metastatic prostate cancer is primarily treated by endocrine manipulation. Complete androgen blockade with analogue of luteinizing hormone releasing hormone (LHRH) or surgical castration and antiandrogens seem to have no advantage over the LHRH analogues or surgical castration alone. The progression to a hormone-refractory state is still a challenging issue for urologists because of the lack of standard therapy.
  Bratislavske lekarske listy 02/2003; 104(4-5):164. · 0.40 Impact Factor
• Article: Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment.

  D Ondrus, J Matoska, V Belan, J Kausitz, F Goncalves, M Hornák
  [show abstract] [hide abstract]
  ABSTRACT: Surveillance after orchiectomy alone becomes popular for the management of clinical stage I nonseminomatous germ cell testicular tumours (CS I NSGCTT). Effort to identify patients at high risk of relapse leads to searching prognostic factors of CS I NSGCTT. The aim of this study was to identify those patients in whom a surveillance policy is less likely to be successful. Seventy-two CS I NSGCTT patients were stratified to different risk-adapted therapeutic approaches according to histopathologic findings of primary tumor removed by inguinal orchiectomy. Eighteen patients (group A) with vascular invasion and majority of embryonal carcinoma component in the primary tumor were treated with adjuvant BEP chemotherapy. None of them experienced disease progression after a median follow-up period of 36 months after orchiectomy. Five patients (group B) with vascular invasion and the majority of teratomatous elements in the primary tumor have been followed up 56 months after orchiectomy. They were treated with primary retroperitoneal lymph node dissection (RPLND). Two of them (40%) had pathologic stage II after RPLND and underwent subsequent chemotherapy. One of them died due to disease progression 29 months following orchiectomy. Another one lives with no evidence of disease (NED). Three patients in pathologic stage I are alive with NED. Forth-nine patients (group C) without vascular invasion have been followed up for a median duration of 37 months after orchiectomy. They were kept under close surveillance, consisted of regular follow-up with tumor markers, chest x-ray and CT of the retroperitoneum. Disease progression was observed in 7 (14.3%) patients after a median duration of 8 months after orchiectomy. They were treated with BEP chemotherapy and live with disease-free median survival of 22 months after completion of therapy. The overall survival rate of all 72 patients was 98.6%. The median survival for all patients was 37 months (range 7-73). The authors will continue to use surveillance policy only in patients without vascular invasion in the primary tumor.
  European Urology 02/1998; 33(6):562-6. · 8.49 Impact Factor
• Article: [Will determination of prostate specific antigen density improve the diagnosis of prostatic carcinoma?].

  F Goncalves, M Hornák, M Miklosi
  [show abstract] [hide abstract]
  ABSTRACT: Prostate specific antigen (PSA) serum levels in patients with prostate carcinoma and with benign prostate hyperplasia overlap. In order to improve the positive predictive value of PSA in the diagnosis of prostate carcinoma the authors recommend to evaluate the PSA levels in relation to the prostate volume, the so-called density of the prostate specific antigen (PSAD). The correlation of PSA and PSAD with results of bioptic examination revealed that PSAD does not increase the capacity of PSA to predict the presence of prostate carcinoma and does not reduce the number of prostate biopsies. All patients with PSA levels higher than 4 ng/ml and/or a pathological finding on digital rectal examination need a bioptic examination of the prostate.
  Rozhledy v chirurgii: měsíčník Československé chirurgické společnosti 10/1997; 76(9):421-4.
• Article: [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens].

  M Hornák, A Bárdos, F Goncalves
  [show abstract] [hide abstract]
  ABSTRACT: Combined androgen blockade using surgical or medical (luteinizing hormone-releasing hormone agonist) castration in association with anti-androgen has become the primary therapy in patients with metastatic prostate cancer. Patients undergoing combined androgen blockade will progress within 18-30 months after initial hormonal therapy. When progression occurs following combined androgen blockade, the non-steroid anti-androgen should be subsequently withdrawn. Several recent reports have been published on the paradoxical effect of anti-androgen withdrawal. Eight (22.9%) of 35 patients showed a decline in PSA levels following flutamide withdrawal. The mean time to progression following combined androgen blockade was 26 month and the mean duration of response to flutamide withdrawal was 4.1 months.
  Rozhledy v chirurgii: měsíčník Československé chirurgické společnosti 10/1997; 76(9):435-7.
• Source

  Available from: aepress.sk

  Article: Adrenal incidentalomas--analysis of 23 cases discovered by ultrasound.

  E Goncalvesová, P Hnilica, Z Motovská, F Goncalves, A Kovác
  [show abstract] [hide abstract]
  ABSTRACT: Frequent use of abdominal ultrasonography (USG) increases discovery of incidental adrenal tumors. Our experience and concise review of recent opinions on management of adrenal incidentalomas is presented. In four out of 23 patients with adrenal incidentalomas false positivity of USG was found (all on the left side), 4 cases were identified as pseudoadrenal masses. Hormonal activity was proved in 4 out of 15 true adrenal masses (2 pheochromocytomass, 2 aldosteronomas). Five out of 11 hormonally inactive tumors were benign adenomass, 2 myelolipomas, 2 simple cysts, 1 metastasis of bronchogenic carcinoma and 1 tuberculotic involvement. The smallest tumor was aldosteronoma (2 cm in diameter), the largest was myelolipoma (more than 10 cm). Size of benign adenomas ranged between 2.5-4.8 cm. Three main ultrasonic patterns of adrenal tumors were recognized: (1) anechogenic cysts, (2) complex but predominantly hyperechogenic myelolipomas, (3) hypoechogenic all other masses.
  Neoplasma 02/1997; 44(2):137-41. · 1.44 Impact Factor
• Article: The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).

  D Ondrus, F Goncalves, J Kausitz, J Mat'oska, V Belan
  [show abstract] [hide abstract]
  ABSTRACT: The prospective study, carried out from February 1992 to January 1996, included 49 patients in clinical Stage I nonseminomatous germ cell testicular tumors (NSGCTT). They were aged 16-40 years (mean, 25 years). Patients were stratified to different risk-adapted therapeutic approaches according to histopathologic findings of primary tumor removed by inguinal orchiectomy. Eleven patients of the 1st group with vascular invasion and majority of embryonal carcinoma components in the primary tumor were treated with adjuvant chemotherapy (2 cycles of BEP). None of them had disease progression after the follow-up of 4-43+ months (mean, 20.9 months) after orchiectomy. Five patients of the 2nd group with vascular invasion and majority of teratoma elements in the primary tumor were treated with primary retroperitoneal lymph node dissection (RPLND). They were followed-up 29-45+ months (mean, 33.4 months) after orchiectomy. Two of them (40%) had pathologic Stage II after RPLND and underwent subsequent BEP chemotherapy. One of them died due to disease progression in disseminated stage 29 months after orchiectomy. The second one lives with no evidence of the disease (NED). Thirty three patients in the 3rd group without vascular invasion were kept under surveillance. They were followed-up 3-48+ months (mean, 22.3 months) after orchiectomy. Disease progression was observed in 5 of them (15.1%), 7-10 months (mean, 8.8 months) following orchiectomy. These patients were treated with BEP chemotherapy and live with NED 1-16+ months (mean, 9.2 months) after completion of the therapy. The overall survival rate in clinical Stage 1 patients was 97.9%. The authors recommend the surveillance policy only in clinical Stage I NSGCTT patients without vascular invasion in the primary tumor.
  Neoplasma 02/1996; 43(3):195-7. · 1.44 Impact Factor
• Article: [Prophylaxis with ciprofloxacin in transurethral surgery].

  M Sobek, M Kontárová, F Goncalves
  [show abstract] [hide abstract]
  ABSTRACT: The purpose of the study was to compare in a prospective randomized study the effect of three doses of prophylactic administration of ciprofloxacin in 25 patients and a control group of 26 patients without prophylactic antibiotic treatment in conjunction with transurethral surgery. In the group of patients with prophylaxis there is a significantly lower incidence of clinical manifestations of infection, as compared with the group of patients without prophylaxis which reduces the necessity to administer antibacterial drugs during the postoperative period.
  Rozhledy v chirurgii: měsíčník Československé chirurgické společnosti 10/1994; 73(6):298-9.
• Article: [Prostate-specific antigen in patients with benign prostatic hyperplasia].

  F Goncalves, J Kausitz, A Bárdos, M Miklosi
  [show abstract] [hide abstract]
  ABSTRACT: The authors examined 119 patients with the histological finding of benign prostatic hyperplasia (BPH). Before the planned operation of the prostate (transurethral resection or open prostatectomy) the authors examined in all patients the level of the prostate specific antigen (PSA) and the prostate volume by sonography. Of 119 patients 70 (58.8%) had elevated serum levels of PSA and in 35 (29.4%) the PSA level was higher than 10 ng/ml. The authors demonstrated a highly significant (p < 0.0001) linear relationship of the PSA serum level and volume of prostate in patients with BPH. Based on the results of simple regression analysis they elaborate an equation for the prostate volume: PSA ng/ml = (3.26 + 0.12 x volume of prostate (ml) +/- 8.44). By adding the value of the standard deviation of PSA the authors created an interval in which are most of the patients with BPH. The authors recommend supplementary examinations (transrectal sonography and biopsy of the prostate) in patients where there is a disproportion between the PSA level and the prostate volume.
  Rozhledy v chirurgii: měsíčník Československé chirurgické společnosti 09/1994; 73(6):291-3.
• Article: [Comparison of urography and ultrasonography findings in patients prior to prostatectomy].

  F Goncalves, A Bárdos
  [show abstract] [hide abstract]
  ABSTRACT: In order to evaluate the assess of ultrasonographic examinations in patients before prostatectomy the authors correlated preoperative findings obtained by urography with ultrasonographic findings. Urography of the upper urinary pathways revealed 12 (18.8%) pathological findings, ultrasonographic examination 26 findings (40.6%) in a group of 64 patients. While in 14 patients a pathological finding on ultrasonography was not revealed by urography, only in one patient with a positive urographic finding ultrasonography was negative. Ultrasonographic examination proved to be more valuable in assessing the post-miction residue, as compared with urography. Moreover, ultrasonography is useful for assessing the volume of tissue of benign prostatic hyperplasia. Correlation of the calculated volume of prostatic tissue by means of ultrasonography with the weight of removed tissue revealed a close linear correlation. Ultrasonographic examination of patients before prostatectomy replaced urography which proved to be unnecessary diagnostic procedure.
  Rozhledy v chirurgii: měsíčník Československé chirurgické společnosti 05/1992; 71(3-4):174-8.
• Article: [Transurethral invaginating ureterectomy].

  F Goncalves, M Hornák, J Reznícek
  [show abstract] [hide abstract]
  ABSTRACT: The principle of transurethral invagination ureterectomy is in the invagination of the stump of the ureter its retraction into the urinary bladder and resection of the levels of the mucosa of the urinary bladder. The authors describe the surgical procedure and experience with the treatment of seven patients.
  Rozhledy v chirurgii: měsíčník Československé chirurgické společnosti 01/1992; 70(12):521-3.